The Galien Foundation has revealed its latest nominees for the 2021 Prix Galien USA Award highlighting innovations in biotechnology, pharmaceutical agents, medical technology and digital health products. Entrants to the competition must have received FDA approval within the past five years and demonstrate exceptional therapeutic potential. The Galien Foundation does not use financial data to…
Nexletol: The first oral, daily, non-statin drug to lower LDL cholesterol
Nexletol is similar to Nexlizet in its FDA indication as an adjunct to diet and statin therapy to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who need additional help lowering of LDL cholesterol. In September, Nexletol began a direct-to-consumer campaign advertising the potential of the drug to support LDL cholesterol-lowering as an adjunct…